Tag: Transgenes
Transgene’s Combined General Meeting of May 5, 2023 – 05/05/2023 at 05:45 PM
Strasbourg, France, May 5, 2023, 05:45 pm CEST – The Combined Ordinary and Extraordinary General Meeting of Transgene’s shareholders was held today (May 5, 2023) at 9:00 am at the…
TRANSGENE: The positive data generated in 2022 with the main clinical candidates confirms Transgene’s outlook for 2023, in a buoyant context for therapeutic vaccines against cancer and oncolytic viruses – 03/16/2023 at 17:45
2022 annual results and activity update – TG4050: New Phase I data confirms the clinical and commercial potential of this innovative personalized immunotherapy. Preparation of a Phase II trial in…
Phase I data of TG6002 presented at ESMO 2022 confirms the potential of Transgene’s Invir.IO™ oncolytic viruses administered intravenously to treat solid tumors – 09/12/2022 at 08:00
The new positive data from the Phase I trial of TG6002 show in all patients that this oncolytic virus, administered intravenously, is capable of reaching the tumor, multiplying there and…